Following an executive order signed by U.S. President Donald Trump aimed at accelerating research and expanding access to certain substances for treating post-traumatic stress disorder (PTSD), shares of companies involved in psychedelic medicine rose sharply in pre-market trading. Among the more volatile individual stocks, Compass Pathways (CMPS.US) climbed 25%, Atai Beckley (ATAI.US) jumped 22%, and Definium Therapeutics (DFTX.US) advanced 20%. GH Research (GHRS.US) and Cybin (HELP.US) each surged 17%. Oppenheimer analyst Jay Olson stated that Trump's executive order "represents a structural inflection point for the U.S. psychedelics industry by promoting research, streamlining regulatory timelines, and expanding patient access, reinforcing our positive outlook." Olson maintained a favorable view on Atai Beckley, Compass Pathways, and Definium Therapeutics, citing their "differentiated advantages." Jefferies analyst Andrew Tsai noted that with alignment across the Trump administration, the Department of Health and Human Services (HHS), the Food and Drug Administration (FDA), and the Department of Veterans Affairs (VA), "investor attention should significantly increase ahead of potential approvals between 2027 and 2030." The report added that "the path to commercialization may now become faster." Meanwhile, RBC Capital Markets analyst Brian Abrahams viewed the executive order as "accelerating the development of psychedelics as the next wave of key mental health treatments." The report highlighted this as another positive development for the sector, benefiting RBC-covered psychedelic companies Definium Therapeutics, Compass Pathways, and GH Research.